Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Late January meeting of FDA advisory panel will review NDAs for ProMem and Novantrone

Dec. 23, 1999

Dexmedetomidine receives FDA marketing approval

Dec. 22, 1999

Parke-Davis identifies atypical antipsychotic with clinical potential

Dec. 21, 1999

Inhibitors of PARP activity continue to emerge from Guilford R&D

Dec. 21, 1999

Schwarz sells intranasal scopolamine rights to Nastech

Dec. 21, 1999

Licensing opportunity from NIH: orally active neuron cell death-inhibitory peptides

Dec. 21, 1999

First human trial of Sheffield's pulmonary delivery system for migraine therapy

Dec. 21, 1999

Add-on stiripentol produces high response rate in intractable epilepsy syndrome

Dec. 20, 1999

New class I mGluR antagonist prevents seizure-induced hippocampal damage

Dec. 20, 1999

Remacemide for resistant epilepsy: preliminary data from meta-analysis

Dec. 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...